Skip to Main Content

Author Details

Alan C Whitmore
University of North Carolina at Chapel Hill
1973
55
28
PMIDPaper TitleJournal TitlePublished Year
32348764Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross.Cell Rep2020
29187420Bayesian Diallel Analysis Reveals <i>Mx1</i>-Dependent and <i>Mx1</i>-Independent Effects on Response to Influenza A Virus in Mice.G3 (Bethesda)2018
30301856Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.mBio2018
29540599Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.J Virol2018
29324290Ross River virus envelope glycans contribute to disease through activation of the host complement system.Virology2018
29138302Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.mBio2017
26015500Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.mBio2015
26491151γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.J Virol2015
26452100Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross.PLoS Genet2015
24667706A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.mBio2014
25266735A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.Cancer Discov2014
24902603Genomic profiling of collaborative cross founder mice infected with respiratory viruses reveals novel transcripts and infection-related strain-specific gene and isoform expression.G3 (Bethesda)2014
23487448Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice.J Virol2013
23468633Modeling host genetic regulation of influenza pathogenesis in the collaborative cross.PLoS Pathog2013
22384400Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice.G3 (Bethesda)2012
22837203Myd88-dependent toll-like receptor 7 signaling mediates protection from severe Ross River virus-induced disease in mice.J Virol2012
22531556Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.Vaccine2012
22457620Mannose binding lectin is required for alphavirus-induced arthritis/myositis.PLoS Pathog2012
20980507Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.J Virol2011
21849461The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection.J Virol2011
21937658A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.J Virol2011
21224040A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.Am J Pathol2011
20386712SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism.PLoS Pathog2010
20181704T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody.J Virol2010
19225006Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis.J Virol2009
19656875Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff.J Virol2009
19793821Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.J Virol2009
19171081An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.Epidemiol Infect2009
17904185Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.Virology2008
18566424Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.J Immunol2008
18582997Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Vaccine2008
18656518The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.Vaccine2008
17275057Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.Virology2007
17913817Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.J Virol2007
17652394An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.J Virol2007
16378976Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis.J Virol2006
17194199Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.PLoS Med2006
16505353Mucosal and systemic adjuvant activity of alphavirus replicon particles.Proc Natl Acad Sci U S A2006
15494487Rapid induction of splenic and peritoneal B-1a cells in adult mice by thymus-independent type-2 antigen.J Immunol2004
8671640Phenotype of B cells responding to the thymus-independent type-2 antigen polyvinyl pyrrolidinone.Int Immunol1996
7680563B-1 cells are made, not born.Immunol Today1993
1376029Isotype switching in CD5 B cells.Ann N Y Acad Sci1992
2049338Ig isotype switching in B lymphocytes. The effect of T cell-derived interleukins, cytokines, cholera toxin, and antigen on isotype switch frequency of a cloned B cell lymphoma.Int Immunol1991
2489041Ig isotype switching in B lymphocytes. A method for estimating isotype switch frequency in cloned B cell lymphomas.Int Immunol1989
3131432Ig isotype switching in B lymphocytes. Isolation and characterization of clonal variants of the murine Ly-1+ B cell lymphoma, CH12, expressing isotypes other than IgM.J Immunol1988
2987113Subline divergence within L.C. Strong's C3H and CBA inbred mouse strains. A review.Immunogenetics1985
6308100Rous sarcoma virus-induced tumours in mice. II. Contribution of H-2 and non-H-2 alloantigen barriers to tumour immunogenicity in vivo.J Immunogenet1983
6284517Rous sarcoma virus-induced tumors in mice--I. Macrophage-mediated natural cytotoxicity.Eur J Cancer Clin Oncol1982
6982816Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells.Eur J Immunol1982
6167622Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: cross-reactivity of the H-2Kbm1 through Kbm4 H-2 mutant alleles in Kb-restricted SV40-specific killing.J Immunol1981
  • 1 - 50 of 55

Recommended Authors

Yale School of Public Health
Career Start Year 2015
Number of shared co-authors 1
Yale University School of Medicine
Career Start Year 2013
Number of shared co-authors 1
St. Jude Children's Research Hospital
Career Start Year 2005
Number of shared co-authors 12
Icahn School of Medicine at Mount Sinaigrid.59734.3c
Career Start Year 2004
Number of shared co-authors 3
Lankenau Institute for Medical Research
Career Start Year 2004
Number of shared co-authors 10
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2001
Number of shared co-authors 3
The University of Texas at Austin
Career Start Year 2000
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 14
Washington University School of Medicine
Career Start Year 1996
Number of shared co-authors 19
National Institute of Allergy and Infectious Diseases
Career Start Year 1995
Number of shared co-authors 4
University Hospital Essen, University of Duisburg-Essen, Institute for Virology
Career Start Year 1993
Number of shared co-authors 2
The University of Alabama at Birmingham
Career Start Year 1990
Number of shared co-authors 0
School of Public Health, University of California berkeley
Career Start Year 1990
Number of shared co-authors 1
Institute for Immunity, Stanford University School of Medicine, Stanford University
Career Start Year 1990
Number of shared co-authors 6
Merck & Co. Inc.
Career Start Year 1987
Number of shared co-authors 0
Wistar Institute
Career Start Year 1986
Number of shared co-authors 2
National Institute of Allergy and Infectious Diseases
Career Start Year 1986
Number of shared co-authors 0
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 0
Washington University School of Medicine
Career Start Year 1982
Number of shared co-authors 28
Pathology Advanced Translational Research Unit, Emory University School of Medicine
Career Start Year 1981
Number of shared co-authors 4
Drukier Institute for Children's Health
Career Start Year 1976
Number of shared co-authors 2
University of California
Career Start Year 1976
Number of shared co-authors 0
Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center
Career Start Year 1975
Number of shared co-authors 2
Vanderbilt University Medical Center
Career Start Year 1975
Number of shared co-authors 9
Tulane University School of Medicine
Career Start Year 1974
Number of shared co-authors 4
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1972
Number of shared co-authors 0
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1971
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1966
Number of shared co-authors 0
University of British Columbia
Career Start Year 1965
Number of shared co-authors 0

Collaborators

University of North Carolina at Chapel Hill.
Co-authored papers 25
University of North Carolina
Co-authored papers 14
University of North Carolina.
Co-authored papers 10
University of North Carolina at Chapel Hill
Co-authored papers 9
University of Colorado Anschutz Medical Campus
Co-authored papers 8
University of North Carolina at Chapel Hill
Co-authored papers 6
University of North Carolina
Co-authored papers 6
College Station
Co-authored papers 5
University of North Carolina at Chapel Hill
Co-authored papers 5
University of Texas Medical Branch
Co-authored papers 5
University of Washington
Co-authored papers 5
The University of North Carolina at Chapel Hill
Co-authored papers 4
Co-authored papers 4
and Lineberger Comprehensive Cancer Center, University of North Carolina System
Co-authored papers 4
National Center for Toxicological Research
Co-authored papers 4
NC State University
Co-authored papers 3
Co-authored papers 3
University of North Carolina at Chapel Hill
Co-authored papers 3
University of North Carolina School of Medicine
Co-authored papers 3
Oregon Health & Science University, University of California Berkeley
Co-authored papers 3
University of North Carolina at Chapel Hill
Co-authored papers 3
Mayo Clinic
Co-authored papers 2
Washington State University
Co-authored papers 2
University of North Carolina at Chapel Hill
Co-authored papers 2
Merck Research Laboratories
Co-authored papers 2
University of North Carolina
Co-authored papers 2
University of Texas Medical Branch
Co-authored papers 2
United States Army Medical Research Institute of Infectious Diseases
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
University of Chicago, Gwen Knapp Center for Lupus Research.
Co-authored papers 2